Table E2.
Baseline characteristics of studies including <250 patients (n = 30)
| Study | Year | Study design (no. centers) | Sample size | Age, y | STS score, % | Inclusion period | Left ventricle ejection fraction, % | Peripheral artery disease, % | Diabetes mellitus, % | Valve type | Follow-up, mo∗ | Approach for TAVI | Mortality at 30 d |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sinhal et alE1 | 2008 | Prospective (1) | 106 | 84.2 | na | na | 62.5 | na | na | 100% SAPIEN | 1 | na | na |
| Jilaihawi et alE2 | 2009 | Retrospective (1) | 30 | 84.4 | 8.3 | January 2007 to March 2008 | 47.5 | na | 17.6 | 100% MCV | na | na | 8.8% |
| Baan et alE3 | 2010 | Retrospective (1) | 34 | 80.4 | 5 | na | na | na | 32 | 100% MCV | 1 | na | 20.5% |
| Fraccaro et alE4 | 2011 | Retrospective (1) | 64 | 81 | na | May 2007 to April 2009 | 52.3 | 34.4 | na | 100% MCV | 12 | 94% transfemoral 6% transsubclavian |
5% |
| Van der boon et alE5 | 2013 | Prospective (1) | 167 | 81 | na | November 2005 to February 2011 | 51 | 10.2 | 21.6 | 100% MCV | 11,5 | 97% transfemoral 3% transsubclavian |
na |
| Pereira et alE6 | 2013 | Retrospective (1) | 65 | 79.3 | na | August 2007 to May 2011 | na | 47.7 | 38.5 | 100% MCV | 6 | 78.5% transfemoral 20% transsubclavian 1.5% direct aortic |
na |
| Goldenberg et alE7 | 2013 | Retrospective (1) | 191 | na | na | February 2009 to July 2012 | na | na | na | 65% MCV 35% SAPIEN |
17 | na | na |
| Ramazzina et alE8 | 2014 | Retrospective (1) | 97 | 83 | na | October 2010 to January 2013 | 55 | na | 26.4 | 61% MCV 39% SAPIEN |
12 | 100% transfemoral | na |
| Boerlage-Van Dijk et alE9 | 2014 | Retrospective (1) | 121 | 80.5 | 4.5 | October 2007 to June 2011 | na | na | 28 | 100% MCV | 12 | 100% Transfemoral | na |
| Renilla et alE10 | 2015 | Retrospective (1) | 95 | na | na | January 2007 to December 2011 | na | na | na | 100% MCV | 35 | 86.9% transfemoral 13% transsubclavian |
na |
| Petronio et alE11 | 2015 | Prospective (9) | 194 | 80.2 | 7.2 | October 2011 to April 2013 | na | 27.6 | 31 | 100% MCV | 1 | 89.7% transfemoral 6.2% transsubclavian 4.1% direct aortic |
1.6% |
| Weber et alE12 | 2015 | Retrospective (1) | 212 | 80.8 | 9.4 | 2008 - 2012 | 52.8 | na | 25 | 100% MCV | 9 | 100% transfemoral | 6.1% |
| Schernthaner et alE13 | 2016 | Retrospective (1) | 153 | 81 | 6 | na | na | na | 31 | 82% MCV 18% SAPIEN |
1,5 | 94% transfemoral 6% direct aortic |
na |
| Kostopoulou et alE14 | 2016 | Prospective (1) | 45 | 81 | na | January 2010 to February 2012 | 49 | na | 27 | 100% MCV | 24 | na | na |
| Sideris et alE15 | 2016 | Prospective (1) | 168 | na | na | January 2009 to October 2015 | na | na | na | 100% MCV | na | 100% transfemoral | na |
| Luke et alE16 | 2016 | Retrospective (1) | 140 | 81 | na | July 2011 to May 2016 | na | na | na | 81% MCV 19% EVOLUT |
na | 100% transfemoral | na |
| Makki et alE17 | 2017 | Retrospective (1) | 172 | 83 | na | November 2011 to January 2016 | 51 | na | 46 | 92% MCV 8% LOTUS |
22 | 100% transfemoral | na |
| Nijenhuis et alE18 | 2017 | Retrospective (1) | 155 | 80.5 | 6 | June 2007 to June 2015 | 59 | 30.3 | 34.8 | na | 24 | na | na |
| Naveh et alE19 | 2017 | Prospective (1) | 110 | 80.7 | na | September 2008 to November 2013 | 57.6 | 23.6 | 30 | 75.5% MCV 24.5% SAPIEN |
12 | 88.2% transfemoral 6.4% transsubclavian 5.5% direct aortic |
na |
| Alasti et alE20 | 2018 | Prospective (1) | 152 | 83.6 | na | April 2012 to October 2016 | 59.2 | 5.3 | 18.7 | 100% LOTUS | 12 | 99.4% transfemoral 0.6% direct aortic |
2.6% |
| Ortak et alE21 | 2018 | Prospective (1) | 66 | 80.4 | 3.7 | 2014 -2016 | 53.2 | na | na | 100% LOTUS | 7 | na | 3.5% |
| Rodes-Cabau et alE22 | 2018 | Prospective (11) |
103 | 80 | 5 | June 2014 to July 2016 | 56 | na | 43 | 14.5% MCV 37% EVOLUT R 51.5% SAPIEN |
12 | 86% transfemoral 10% transapical 4% transsubclavian |
na |
| Leong et alE23 | 2018 | Retrospective (1) | 67 | 80.5 | na | January 2013 to December 2015 | na | na | 30 | 16.4% EVOLUT R 35.8% MCV 34.3% SAPIEN 13.4% Others |
2,4 | na | na |
| Sharma et alE24 | 2018 | Prospective (1) | 226 | 81.2 | na | March 2012 to October 2016 | na | na | na | 100% BE | 1 | na | na |
| Bacik et alE25 | 2018 | Prospective (1) | 116 | 77.1 | na | August 2013 to Mar 2017 | 50.5 | na | 40.5 | 100% SAPIEN | 12 | 82.8% transfemoral 17.2% transapical |
na |
| Megaly et alE26 | 2019 | Prospective (1) | 172 | na | na | January 2010 to May 2017 | na | na | 50 | na | 12 | na | na |
| Yazdchi et alE27 | 2019 | Retrospective (1) | na | na | na | 2013 - 2017 | na | na | na | na | 14 | na | na |
| McCaffrey et alE28 | 2019 | Retrospective (1) | 98 | 79.6 | 5 | May 2015 to March 2018 | 55.7 | 26 | 35 | 100% SAPIEN | 1 | 93% transfemoral 6% transapical 1% direct aortic |
4.8% |
| Miura et alE29 | 2019 | Retrospective (1) | 201 | 84.8 | 6.4 | October 2013 to September 2016 | 60.6 | 9 | 26 | 100% SAPIEN | 13.5 | 68% transfemoral l 27% transapical 5% transiliac |
0.5% |
| Dhakal et alE30 | 2020 | Retrospective (1) | 176 | 80 | 5.7 | Seprember 2012 to March 2017 | 53 | 31 | 43 | na | 18.9 | na | na |
| Total | na | 49 centers | 3612 | 81.2 | 6 | November 2005 to March 2018 | 54.4 | 24.5 | 32.1 | 65.6% MCV 23.1% SAPIEN 8% LOTUS 2.7% EVOLUT 0.5% Others |
11.4 | 92.5% transfemoral 3% transsubclavian 1% direct aortic 3.2% transapical 0.3% transiliac |
6% |
Values are n (%). STS score, Society of Thoracic Surgeons Risk Score; TAVI, transaortic valve implantation; na, not available; MCV, Medtronic CoreValve.
∗
Follow-up is reported as mean or median as given by the authors.